Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) Equity Average (2016 - 2025)

Historic Equity Average for Abvc Biopharma (ABVC) over the last 12 years, with Q3 2025 value amounting to $12.0 million.

  • Abvc Biopharma's Equity Average rose 59955.55% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 59955.55%. This contributed to the annual value of $1.2 million for FY2024, which is 4477.0% down from last year.
  • As of Q3 2025, Abvc Biopharma's Equity Average stood at $12.0 million, which was up 59955.55% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Equity Average peaked at $12.0 million during Q3 2025, and registered a low of $677596.0 during Q2 2023.
  • Moreover, its 5-year median value for Equity Average was $4.5 million (2022), whereas its average is $4.8 million.
  • In the last 5 years, Abvc Biopharma's Equity Average soared by 67740.13% in 2021 and then crashed by 9191.47% in 2023.
  • Abvc Biopharma's Equity Average (Quarter) stood at $8.7 million in 2021, then tumbled by 48.87% to $4.5 million in 2022, then increased by 15.95% to $5.2 million in 2023, then crashed by 72.3% to $1.4 million in 2024, then skyrocketed by 736.16% to $12.0 million in 2025.
  • Its Equity Average was $12.0 million in Q3 2025, compared to $8.7 million in Q2 2025 and $4.6 million in Q1 2025.